Anupam Rasayan India Limited will host an earnings call on Friday, August 14, 2026, at 02:00 PM IST to discuss its unaudited financial results for the quarter ended June 30, 2026. The event provides stakeholders with a direct opportunity to review the company’s standalone and consolidated performance for Q1FY27, offering clarity on operational metrics and financial health ahead of further market analysis.

The intimation was issued pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Anupam Rasayan India Limited submitted the notice to both BSE Limited and the National Stock Exchange of India Limited on August 11, 2026. The company confirmed that a copy of the invitation is available on its website at www.anupamrasayan.com , ensuring transparency and accessibility for all registered shareholders and investors.

Key Participants

Senior leadership will lead the discussion, offering detailed commentary on the quarterly outcomes. The participant list includes:

• Anand Desai, Managing Director
• Gopal Agrawal, Chief Executive Officer
• Amit Khurana, Chief Financial Officer
• Vishal Thakkar, Deputy Chief Financial Officer

These executives are expected to address strategic initiatives, margin dynamics, and sector-specific challenges impacting the chemical manufacturing business during the fiscal year.

Call Access Details

Investors can join the conference call via pre-registration or by dialing the provided access numbers. The company has arranged multiple lines for domestic and international participants to facilitate broad engagement.

Strategic Growth Advisors Pvt. Ltd is managing the RSVP process. Investors requiring assistance may contact Mr. Shrikant Sangani or Ms. Shaily Patwa at +91 9619595686 or +91 9819494608 respectively.

Regulatory Compliance

The disclosure aligns with mandatory reporting standards under the SEBI Listing Regulations. Ashish Gupta, Company Secretary & Compliance Officer, signed the intimation on behalf of Anupam Rasayan India Limited. The company’s registered office is located in Surat, Gujarat, and it holds the Corporate Identity Number L24231GJ2003PLC042988.

Anupam Rasayan India Ltd has revised the schedule for its mandatory open offer to acquire 26.00% of the expanded voting share capital of Bliss GVS Pharma Limited, extending the tendering period to commence on July 28, 2026, and close on August 10, 2026. The acquirer, along with its wholly-owned subsidiary Mates Visa Consultancy Private Limited designated as a person acting in concert (PAC), is offering ₹299.00 per equity share for up to 2,77,26,848 shares. This update follows the receipt of final observations from the Securities and Exchange Board of India (SEBI) on July 10, 2026, and the subsequent publication of the Letter of Offer on July 18, 2026.

The Committee of Independent Directors (IDC) of Bliss GVS Pharma Limited unanimously recommended the open offer to public shareholders on July 22, 2026. While the IDC deemed the offer price of ₹299.00 fair and reasonable under the regulatory framework of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, it highlighted that the closing market prices on July 17, 2026, were significantly higher at ₹482.50 on the BSE and ₹483.50 on the NSE. The offer price was determined as the highest of the applicable pricing parameters, including the negotiated price under the Share Purchase Agreement (SPA).

Revised Schedule of Activities

The pre-offer advertisement cum corrigendum outlines key changes to the original timeline due to delays in SEBI’s feedback process. The identified date for determining eligible public shareholders remains July 14, 2026. All public shareholders, including those who acquired shares after this date or did not receive the Letter of Offer, are eligible to participate during the tendering period.

Transaction Structure and Pricing

The open offer is triggered by Anupam Rasayan’s acquisition of control over Bliss GVS Pharma through the purchase of 4,58,03,024 equity shares, representing 43.11% of the target company’s capital. Under the SPA, Anupam Rasayan assigned its right to acquire these shares to Mates Visa Consultancy Private Limited, which executed a Deed of Adherence on July 17, 2026. Consequently, all shares validly tendered in the open offer will be acquired by the PAC.

The offer is not conditional upon any minimum level of acceptance. SBI Capital Markets Limited serves as the manager to the open offer, while MUFG Intime India Private Limited acts as the registrar. The total fully paid-up share capital of Bliss GVS Pharma stands at ₹10,62,43,972, divided into 10,62,43,972 equity shares of ₹1 each. No partly paid-up shares, outstanding convertible securities (other than employee stock options), or warrants exist as of the Letter of Offer date.

Analytical Observation: Market Premium vs. Offer Price

A critical aspect of this transaction is the significant discount of the offer price relative to recent market trading levels. The volume-weighted average price on the NSE over the 60 days preceding the public announcement was ₹247.55, which formed the baseline for the regulatory pricing floor. However, the market price surged to approximately ₹483 by mid-July, creating a premium of roughly 62% over the ₹299 offer price. This divergence suggests that market participants may have priced in synergies or future prospects not reflected in the statutory offer valuation. Public shareholders must weigh the certainty of the cash exit against the potential upside of holding shares in a controlled entity, particularly given the IDC’s explicit warning about the higher market prices.